HRTX

Heron Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →

YES
43.5% BELOW
↓ Approaching Was -41.4% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $2.23
14-Week RSI 55

Heron Therapeutics, Inc. (HRTX) closed at $1.26 as of 2026-02-02, trading 43.5% below its 200-week moving average of $2.23. This places HRTX in the extreme value zone. The stock is currently moving closer to the line, down from -41.4% last week. The 14-week RSI sits at 55, indicating neutral momentum.

Over the past 1958 weeks of data, HRTX has crossed below its 200-week moving average 28 times. On average, these episodes lasted 51 weeks. Historically, investors who bought HRTX at the start of these episodes saw an average one-year return of +28.2%.

With a market cap of $231 million, HRTX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. The stock trades at 33.2x book value.

Share count has increased 49.1% over three years, indicating dilution.

Over the past 33.2 years, a hypothetical investment of $100 in HRTX would have grown to $0, compared to $2849 for the S&P 500. HRTX has returned -17.3% annualized vs 10.6% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $6,230,657. Notably, these purchases occurred while HRTX is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.

Growth of $100: HRTX vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After HRTX Crosses Below the Line?

Across 25 historical episodes, buying HRTX when it crossed below its 200-week moving average produced an average return of +28.6% after 12 months (median -15.0%), compared to +13.5% for the S&P 500 over the same periods. 44% of those episodes were profitable after one year. After 24 months, the average return was +4.6% vs +31.2% for the index.

Each line shows $100 invested at the moment HRTX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

2 conviction buys in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2025-08-08RUBRIC CAPITAL MANAGEMENT L.P.Beneficial Owner of more than 10% of a Class of Security$3,580,8382,387,225+8.6%
2025-08-08MORGAN ADAMDirector$2,649,8191,766,546+24.8%

Historical Touches

HRTX has crossed below its 200-week MA 28 times with an average 1-year return of +28.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Sep 1988Jan 19891527.3%N/A-99.8%
Mar 1989Mar 198910.0%-34.5%-99.8%
Jun 1989Sep 199111764.6%-1.8%-99.8%
Mar 1993May 1993719.5%+9.8%-99.8%
May 1993Jun 199321.0%-20.4%-99.8%
Jun 1993Mar 19943726.6%-19.2%-99.8%
Mar 1994Sep 19957743.8%-33.7%-99.7%
Oct 1995Jan 19961323.6%+23.8%-99.8%
Dec 1997Feb 199887.6%-14.2%-99.8%
Jun 1998Oct 200327876.3%-10.7%-99.8%
Nov 2003Dec 200337.9%-44.1%-99.3%
Dec 2003Dec 200310.8%-28.6%-99.3%
Aug 2004Jan 20052443.0%+31.8%-98.8%
Feb 2005Jan 20064826.5%+5.5%-99.2%
May 2006Jun 201231989.0%-45.3%-99.1%
Jul 2012Jul 201210.6%-27.4%-89.8%
Oct 2012Jan 20131417.4%-40.7%-89.3%
Mar 2013Jan 20144547.8%+31.2%-88.5%
Jul 2014Aug 201457.2%+301.0%-85.9%
Sep 2014Dec 20141321.9%+319.2%-86.1%
Jan 2015Feb 2015412.2%+185.7%-84.2%
Oct 2016Nov 201622.1%-0.3%-91.7%
Dec 2016Jul 20173219.9%+7.0%-91.5%
Jul 2017Nov 2017169.2%+126.6%-92.2%
Dec 2017Dec 201727.5%+66.5%-92.1%
Apr 2019Oct 20192624.8%-19.4%-92.6%
Jan 2020Jan 202011.2%-6.7%-94.0%
Jan 2020Ongoing315+93.8%Ongoing-94.0%
Average51+28.2%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02